Skip to main content

New treatment for Crohn’s disease

Mar. 22, 2016, 10:00 AM

(iStock)

Crohn’s disease – a chronic inflammatory disease of the digestive tract – causes abdominal pain, diarrhea and weight loss. Immunosuppressive and anti-inflammatory treatments fail in up to 40 percent of patients. In clinical trials, ustekinumab, a new biological therapy that is approved for treatment of psoriasis, is inducing and maintaining remission in Crohn’s disease.

Kimberly Harris, M.D., and colleagues conducted a retrospective chart review to evaluate the effectiveness of ustekinumab in the treatment of Crohn’s disease. Patients received a novel subcutaneous dosing schedule that was designed to match the intravenous dose being used in clinical trials. The investigators found that out of 45 patients who were resistant to other therapies, including anti-TNFs, 46 percent achieved a clinical response, and 35 percent achieved clinical remission. Laboratory and endoscopic markers of Crohn’s disease were also reduced.

The findings, reported in the February issue of Inflammatory Bowel Diseases, demonstrate that a subcutaneous dosing schedule of ustekinumab was successful in improving markers of disease activity in patients with severe, refractory Crohn’s disease.

Send suggestions for articles to highlight in Aliquots and any other feedback about the column to aliquots@vanderbilt.edu

Recent Stories from VUMC News and Communications Publications

Marissa Benchea has CF, and she is one of hundreds of thousands of adults not only surviving but thriving with a chronic childhood disease.

Vanderbilt Medicine

Marissa Benchea has CF, and she is one of hundreds of thousands of adults not only surviving but thriving with a chronic childhood disease.

One hundred years ago, multiple “waves” of a deadly flu swept across the world.

Vanderbilt Medicine

One hundred years ago, multiple “waves” of a deadly flu swept across the world.

A diagnosis of cancer at any age is tragic, but during the adolescent and young adult years, it’s especially complicated.

Hope

A diagnosis of cancer at any age is tragic, but during the adolescent and young adult years, it’s especially complicated.

Karen Dyer Young cares for patients and members of the Dayani Center who have or are recovering from cancer or a stem cell transplant.

Momentum

Karen Dyer Young cares for patients and members of the Dayani Center who have or are recovering from cancer or a stem cell transplant.

more